WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

A New Computer-Modelling Tool to Improve Psoriasis Management and Treatment Outcomes

Details
Research
23 September 2008
At the 17th EADV Conference in Paris, LEO Pharma has unveiled a new weapon in its long-running campaign to improve psoriasis management and treatment outcomes. However, the weapon is not a new drug but a ground-breaking computer-modelling tool, designed to help those involved in the assessment, planning and provision of psoriasis treatment in primary care to balance optimum outcomes with the growing need for cost control.
Read more ...

Genzyme Marks Grand Opening of New Science Center

Details
Research
23 September 2008
Genzyme Corp.Genzyme Corp. (Nasdaq:GENZ) has marked the grand opening of its new Science Center in Framingham, Mass. The facility serves as a central site for early stage research, where scientists are utilizing the most advanced technologies available to discover novel new treatments for devastating diseases such as Parkinson's, cancer, and heart disease.
Read more ...

A project coordinated by VTT turns plant cells into medical factories

Details
Research
20 September 2008
VTT Technical Research Centre of Finland will coordinate the large EU research project called SmartCell. The four-year project focuses on developing methods for production of valuable pharmaceutical compounds using plant cells as a production host in an effective and controlled manner.
Read more ...

New EudraLex CD v 18 CD with the Pharmaceutical Legislation now available for download

Details
Research
19 September 2008
European UnionNow, you can create your own CD with the whole European Union Pharmaceutical Legislation (Human and Veterinary) and an integrated search engine. The CD content is similar to the EudraLex web site, but it can be used off-line with the search engine. All the documents are in .pdf format and without protection.
Read more ...

Top Pharmaceutical Websites Visited by European Consumers Revealed

Details
Research
16 September 2008
Manhattan ResearchManhattan Research, a leading provider of access to physician and consumer opinions on the global healthcare market, reveals today the top pharmaceutical web sites visited by European consumers. Bayer moves into the top spot from last year's ranking at #2. Roche and Pfizer take this year's second and third spots respectively.
Read more ...

FDA to Post Quarterly Report of Potential Safety Issues

Details
Research
08 September 2008
The U.S. Food and Drug AdministrationThe U.S. Food and Drug Administration announced that it has posted on its Web site its first quarterly report that lists certain drugs that are being evaluated for potential safety issues. The drugs have been identified based on a review of reports in FDA's Adverse Event Reporting System (AERS).
Read more ...

Nature inspires new highly specific drugs and organic products

Details
Research
06 September 2008
The best place to seek novel compounds for pharmaceutical drugs, alternative energy sources, and a host of industrial applications, is within natural systems that have evolved over millions of years. Scientists now realise that the precise molecular arrangements within natural pathways in organisms have been highly tuned for specific processes and provide both compounds that can be exploited directly and vital information over how to synthesise new products by mimicking biochemical processes.
Read more ...

More Pharma News ...

  1. Study overturns century-old rule of pharmacology
  2. Manhattan Research's ePharma Physician® study ranks the top online journals by physician visitation
  3. Abcam and Transinsight Collaborate in the Area of Semantic Search Technologies
  4. Physicians Expect to Shift More Time to Online Professional Resources in the Coming Years
  5. European researchers advance bone implants technology
  6. Collexis' BiomedExperts Rapidly Expanding its User Base
  7. First call for Innovative Medicines Initiative a success
  • Start
  • Prev
  • 293
  • 294
  • 295
  • 296
  • 297
  • 298
  • 299
  • 300
  • 301
  • 302
  • Next
  • End
Tahmeena

Business & Industry

  • AMJEVITA™ (adalimumab-atto), first biosimilar to Humira® now available in the United States
  • CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
  • Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above
  • Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries
  • Acquisition of Neogene Therapeutics completed

Research & Development

  • Antidepressants used for chronic pain on the rise, but are they effective?
  • Keys to making immunotherapy work against pancreatic cancer found in tumor microenvironment
  • Discovery of anti-cancer chemistry makes skullcap fit for modern medicine
  • Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future
  • Power of cancer drugs may see boost by targeting newly ID'd pathway
  • A soybean protein blocks LDL cholesterol production, reducing risks of metabolic diseases
  • 500,000 missed out on blood pressure lowering drugs during pandemic

Conferences & Events

  • SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
  • SAE Media Group's 6th annual 3D Cell Culture Conference
  • CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
  • 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
  • CPHI Excellence in Pharma Award Winners 2022
  • CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
  • CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index

Regulatory Affairs

  • FDA grants Accelerated Approval for Alzheimer's disease treatment
  • FDA approves new HIV drug for adults with limited treatment options
  • FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
  • FDA approves first gene therapy to treat adults with Hemophilia B
  • FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
  1. You are here:  
  2. Home
  3. Research
  4. Treating cancer by sticking cells in place

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2023. All Rights Reserved.